Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects
brief summary
To assess subject-centric evidence of QoL outcomes in a subset of subjects enrolled in the global Phase 3 AU-011-301 clinical trial.
detailed description
The AU-011-404 study complements the AU-011-301 clinical trial and aims to identify the broader impact of bel-sar treatment on subjects' daily lives and overall well-being through the collection of PROs. This noninterventional PRO study will provide valuable insights of treatment impact by capturing subject perspective on aspects including symptom management, functional status, and overall health-related quality of life (HRQOL).
The sites will direct interested participants to the study via a unique URL. Upon accessing the URL, participants will be asked to review/sign an informed consent document (ICD). Alternatively, subjects may review and sign a paper version of the informed consent document. Eligible participants will then be asked to answer custom survey questions followed by the EORTC QLQ-C30 and the EORTC QLQ-OPT30 questionnaires at required visits for up to 24 months.